Cancer Vaccines with Potential

Premium

When Dendreon came out with its prostate cancer vaccine Provenge, researchers jumped on the vaccine bandwagon and Wall Street salivated at the thought of the billions of dollars it was going to make, says Robert Langreth at the Forbes Treatments blog. But the complicated preparation for the treatment and the $93,000 price tag — not to mention confusion over how it works since it extends life without slowing tumor growth — have caused big pharmaceutical companies to shy away from trying to develop a vaccine of their own, Langreth adds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.